title: Comparison of the effects of high dose Estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: an interim analysis of EORTC-GU Group study no. 30865.
abstract: Patients with hormone escaped advanced progressive prostate cancer were randomized either to receive either high-dose Estramustine phosphate orally or Mitomycin C by i.v. injection every 6 weeks until signs of progression or death supervened. Patients on both arms progressed rapidly, with a median time to progression of 5 months and a median length of survival of only 10 months. Toxicity was very considerable in both arms.
authors: Princess Royal Hospital, Hull, England.
authors: D W
authors: DW
authors: Newling
authors: S
authors: S
authors: Fossa
authors: U
authors: U
authors: Tunn
authors: K H
authors: KH
authors: Kurth
authors: M
authors: M
authors: De Pauw
authors: R
authors: R
authors: Sylvester
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D005060:Europe / Q000453:epidemiology; D006801:Humans; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000556:secondary; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D008937:Mitomycins; D004961:Estramustine; D016685:Mitomycin